UK markets open in 2 hours 45 minutes

BMY Jun 2025 45.000 call

OPR - OPR Delayed price. Currency in USD
Add to watchlist
4.6800-0.1200 (-2.50%)
As of 11:22AM EDT. Market open.
Full screen
Previous close4.8000
Open4.4100
Bid4.4500
Ask4.7000
Strike45.00
Expiry date2025-06-20
Day's range4.4100 - 4.6800
Contract rangeN/A
Volume2
Open interest117
  • GlobeNewswire

    Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

    Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer

  • Insider Monkey

    Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript

    Bristol-Myers Squibb Company (NYSE:BMY) Q1 2024 Earnings Call Transcript April 25, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is $-4.4, expectations were $-4.55. Bristol-Myers Squibb Company isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Bristol-Myers […]

  • Zacks

    Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It

    Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.